Ajanta Pharma Share Price Prediction 2027: Scenario Targets, Valuation and Technical Outlook

The Ajanta Pharma share price forecast comes down to earnings growth and the multiple investors pay for it, and the reported numbers give a measured answer. The stock trades at Rs 3,373.30 on NSE as of 9 October 2026, 11.1% below its 52-week high of Rs 3,796.00, after the company reported net profit of Rs 1,056 crore for FY26.

This Ajanta Pharma stock forecast 2027 builds conservative, base and bull scenarios from exchange-reported financials, shareholding data and daily price indicators, with every assumption shown.

Click Here – Get Free Investment Predictions

Ajanta Pharma Share Price Today and Key Data

The Ajanta Pharma share price today is Rs 3,373.30 on NSE, down 1.81% on the day. The market capitalisation stands at Rs 42,952 crore. Over the past year the price has risen 39.3% from Rs 2,421.20. Every Ajanta Pharma stock forecast figure below starts from this price.

Metric	Value
Company	Ajanta Pharma (AJANTPHARM)
Current Price	Rs 3,373.30
52-Week High	Rs 3,796.00 (18 August 2026)
52-Week Low	Rs 2,380.20 (14 October 2025)
Market Cap	Rs 42,952 crore
PE Ratio	37.85
Industry PE	37.59
PB Ratio	9.49
EPS (TTM)	Rs 90.82
Return on Equity	23.33%
Debt to Equity	0.06
Dividend Yield	0.82%
Book Value per Share	Rs 362.28

What Is the Ajanta Pharma Share Price Prediction for 2027?

The Ajanta Pharma share price prediction for 2027 is a conservative case of Rs 3,756, a base case of Rs 3,817 and a bull case of Rs 3,877. Against Rs 3,373.30, these imply 11.3% upside, 13.2% upside and 14.9% upside. They are model scenarios built from reported EPS growth, not broker targets.

Scenario	EPS Growth Basis	EPS Estimate	PE Multiple	Implied Value	Upside vs Current Price
Conservative Case	Lower of FY26 growth (14.9%) and 4-year CAGR (11.4%)	Rs 101.13 (+11.4%)	Unchanged from today (price to EPS ratio kept constant)	Rs 3,756	+11.3%
Base Case	Average of the two	Rs 102.76 (+13.1%)	Unchanged from today (price to EPS ratio kept constant)	Rs 3,817	+13.2%
Bull Case	Higher of the two	Rs 104.38 (+14.9%)	Unchanged from today (price to EPS ratio kept constant)	Rs 3,877	+14.9%

Each target takes today's price of Rs 3,373.30 and scales it by the EPS growth assumed for that case, which is the same as holding the PE multiple constant. The conservative case uses the lower of the FY26 EPS growth and the 4-year EPS CAGR, the base case uses their average and the bull case uses the higher figure. Together they form the Ajanta Pharma target price range for the FY27 outlook over the next 12 months, and the range is not a point estimate.

Ajanta Pharma Share Price Forecast: What Has to Go Right by 2027

Each Ajanta Pharma target price below depends on a specific EPS outcome, and the text states that outcome next to the number.

Conservative Case for the Ajanta Pharma Share Price Target: Rs 3,756

Reaching Rs 3,756 needs EPS to rise 11.4% to Rs 101.13 while the stock keeps its current PE multiple. That follows the slower 4-year EPS CAGR of 11.4%.

Base Case for the Ajanta Pharma Share Price Target: Rs 3,817

Reaching Rs 3,817 needs EPS to rise 13.1% to Rs 102.76, the average of the FY26 growth rate and the 4-year CAGR. Net profit growth of 30.9% in Q1 FY27 is at or above that pace, which supports the target.

Bull Case for the Ajanta Pharma Share Price Target: Rs 3,877

Reaching Rs 3,877 needs EPS to rise 14.9% to Rs 104.38 with the PE multiple held at today's level. That is above the 52-week high of Rs 3,796.00, so it would need a fresh breakout. A daily close above the nearest resistance level of Rs 3,543.36 (50-day SMA) would be the first technical confirmation.

Ajanta Pharma Financial Performance: Revenue, Profit and Margins

Ajanta Pharma earned net profit of Rs 1,056 crore on revenue of Rs 5,624.93 crore in FY26, with profit up 14.7% and revenue up 18.6% compared with FY25. Diluted EPS was Rs 84.51 against Rs 73.53 a year earlier, and that earnings base anchors the Ajanta Pharma share price forecast.

Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Operating Margin	Net Margin
FY22	3,456.67	712.68	54.96	31.28%	20.62%
FY23	3,841.28	587.98	45.89	23.56%	15.31%
FY24	4,293.31	816.17	64.77	29.86%	19.01%
FY25	4,742.60	920.39	73.53	29.13%	19.41%
FY26	5,624.93	1,056.00	84.51	28.74%	18.77%

In the latest reported quarter, Q1 FY27 (quarter ended June 2026), revenue was Rs 1,696.86 crore against Rs 1,328.98 crore a year earlier (+27.7%), and the bottom line was a net profit of Rs 334.22 crore against a net profit of Rs 255.34 crore (+30.9%). Operating margin was 30.41% versus 28.99% in the year-ago quarter. Cash flow from operations was Rs 529.19 crore in FY26 against Rs 1,157.23 crore in FY25. Together these figures set the earnings base for the Ajanta Pharma share price prediction.

Check the Univest Screener for live Ajanta Pharma fundamentals

Is Ajanta Pharma Overvalued or Undervalued Right Now?

Ajanta Pharma trades at a PE of 37.85 against an industry PE of 37.59, which places the stock in line with the industry average. The price-to-book ratio is 9.49 on a book value of Rs 362.28 per share. Return on equity of 23.33% means the company earns Rs 23.33 of profit for every Rs 100 of shareholder equity.

Debt to equity is 0.06, so borrowings equal about 6% of shareholder equity. The company declared a dividend of Rs 28.00 per share for FY26, a yield of 0.82% at the current price. This valuation context frames the Ajanta Pharma stock price prediction for 2027 without relying on any outside forecast.

Ajanta Pharma Stock Analysis: Technical Outlook

Ajanta Pharma stock trades below its 50-day SMA of Rs 3,543.36 and above its 200-day EMA of Rs 3,171.69, and the combined daily indicators read bearish. The 52-week high of Rs 3,796.00 was set on 18 August 2026, while the 52-week low of Rs 2,380.20 came on 14 October 2025.

Indicator	Reading	Signal
RSI (14)	35.95	Weak momentum
MACD (12,26,9)	-13.98 vs signal 1.66	Bearish
ADX (14)	19.86	Weak trend
Supertrend (10,3)	Price below Rs 3,740.42	Bearish
50-day SMA	Rs 3,543.36	Price below
200-day EMA	Rs 3,171.69	Price above

The nearest support level sits at Rs 3,171.69 (200-day EMA) and Rs 2,380.20 (52-week low). The nearest resistance level sits at Rs 3,543.36 (50-day SMA) and Rs 3,740.42 (Supertrend). A sustained move above the nearest resistance would support the Ajanta Pharma share price prediction 2027 base case, and this Ajanta Pharma stock analysis uses daily candles only. Chart signals add context to the Ajanta Pharma share price target without changing the earnings maths.

Ajanta Pharma Shareholding Pattern

Promoters hold 63.48% of Ajanta Pharma as of Jun 2026, down from 66.26% in Jun 2025 across the last 5 quarters. FII holding is 7.68% (down from 8.86% in Jun 2025) and DII holding is 21.80% (up from 17.50% in Jun 2025), which puts combined institutional holding at 29.48%. Public shareholders own 7.03%. Shareholding data is one input for any Ajanta Pharma stock forecast.

Key Risks to the Ajanta Pharma Share Price Target for 2027

Earnings and Margin Risk

Operating margin has ranged from 23.56% to 31.28% between FY22 and FY26, so a slip toward the lower end would trim the EPS estimate behind the Ajanta Pharma stock forecast. Revenue was up 18.6% in FY26, and slower revenue growth would weigh on the profit path.

Size and Liquidity Risk

Market capitalisation stands at Rs 42,952 crore. Investors should check daily traded volumes and order book depth on NSE before sizing a position, because price moves can be sharper when volumes thin out. Liquidity is a practical constraint on any Ajanta Pharma stock price target.

Balance Sheet Risk

Debt to equity of 0.06 means borrowings stand at about 6% of shareholder equity. A rise in borrowing costs or a jump in debt would weigh on profit and on the multiple behind the Ajanta Pharma share price forecast.

Technical Risk

The daily indicators read bearish, so the targets above may need a technical turn before the price follows earnings. A daily close below Rs 3,171.69 (200-day EMA) would weaken the setup further.

Conclusion

This Ajanta Pharma stock analysis puts the share price target range for 2027 at Rs 3,756 to Rs 3,877, with a base case of Rs 3,817 against Rs 3,373.30 today. The inputs are a PE of 37.85 that sits in line with the industry average, EPS growth of 14.9% in FY26 and a daily technical setup that reads bearish. The next quarterly result will show which scenario is gaining ground. This analysis is educational, so consult a SEBI-registered advisor before acting on it.

Download the Univest iOS App or Univest Android App to track Ajanta Pharma live price and get daily stock recommendations.

Frequently Asked Questions on Ajanta Pharma Share Price Prediction 2027

What is the Ajanta Pharma share price target for 2027?

Ans. The Ajanta Pharma share price forecast for 2027 has a conservative case of Rs 3,756, a base case of Rs 3,817 and a bull case of Rs 3,877. These are model scenarios based on reported EPS growth, and they are not guaranteed outcomes.

What is the Ajanta Pharma share price today?

Ans. Ajanta Pharma trades at Rs 3,373.30 on NSE as of 9 October 2026, down 1.81% on the day. The 52-week range is Rs 2,380.20 to Rs 3,796.00.

Is Ajanta Pharma a good stock to buy for 2027?

Ans. The data points in different directions: the PE of 37.85 is in line with the industry average, EPS grew 14.9% in FY26 and the daily technical setup reads bearish. This article does not constitute investment advice, so consult a SEBI-registered advisor before deciding.

Can Ajanta Pharma stock reach Rs 3,877 in 2027?

Ans. Reaching Rs 3,877 needs EPS to rise 14.9% from Rs 90.82 with the PE multiple held at today's level, plus a daily close above Rs 3,543.36 (50-day SMA). This is a scenario, not a guarantee.

What are the support and resistance levels for Ajanta Pharma?

Ans. The nearest support levels are Rs 3,171.69 (200-day EMA) and Rs 2,380.20 (52-week low), and the nearest resistance levels are Rs 3,543.36 (50-day SMA) and Rs 3,740.42 (Supertrend).

What are the main risks for Ajanta Pharma stock in 2027?

Ans. The main risks to the Ajanta Pharma share price forecast are a fall in operating margin from the 23.56% to 31.28% range seen since FY22, slower revenue growth after FY26 revenue was up 18.6%, and thin trading volumes. Debt to equity of 0.06 adds balance sheet sensitivity.

How is the Ajanta Pharma target price for 2027 calculated?

Ans. Each target scales the current price by assumed EPS growth at a constant PE multiple. The conservative case uses 11.4% growth, the base case 13.1% and the bull case 14.9%, all drawn from the company's reported FY26 and 4-year EPS growth.